Beta-blockers for hypertension (Review)

by Wiysonge CS, Bradley HA, Volmink J et al.
Cochrane Database of Systematic Reviews 2017, Issue 1

96 pp. 1.0 MB
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002003.pub5/abstract

Most outcome randomised controlled trials (RCTs) on beta-blockers as initial therapy for hypertension have high risk of bias. Atenolol was the beta-blocker most used. Current evidence suggests that initiating treatment of hypertension with beta-blockers leads to modest cardiovascular disease (CVD) reductions and little or no effects on mortality. These beta-blocker effects are inferior to those of other antihypertensive drugs. Further research should be of high quality and should explore whether there are differences between different subtypes of beta-blockers or whether beta-blockers have differential effects on younger and older people.

(Visited 22 times, 1 visits today)
This entry was posted in General, Non-communicable Diseases. Bookmark the permalink.